This page provides a comprehensive overview of clinical trials investigating brain-computer interface (BCI) technologies for neurodegenerative diseases. BCI-based interventions represent a promising therapeutic approach for conditions including Parkinson's disease, Alzheimer's disease, ALS, and stroke-related neurological deficits.
| Trial Name |
Device/Intervention |
Phase |
Status |
NCT Number |
| Neuralink PRIME Study |
N1 Implant |
Phase 1 |
Recruiting |
NCT06319728 |
| Adaptive DBS for PD |
Closed-loop DBS |
Phase 2 |
Recruiting |
NCT05873964 |
| Stentrode Motor Control |
Synchron Stentrode |
Phase 1 |
Recruiting |
NCT05196074 |
| Trial Name |
Device/Intervention |
Phase |
Status |
NCT Number |
| BrainGate2 |
Utah Array |
Early Phase 1 |
Recruiting |
NCT00912041 |
| Neuralink Telepathy |
N1 Implant |
Phase 1 |
Recruiting |
NCT06319728 |
| Synchron COMMANDER |
Stentrode |
Phase 1 |
Recruiting |
NCT05028261 |
| Trial Name |
Device/Intervention |
Phase |
Status |
NCT Number |
| BCI-Assisted Motor Recovery |
EEG-Based BCI |
Phase 2 |
Recruiting |
NCT05882338 |
| Motor Imagery BCI Rehab |
MI-BCI + FES |
Phase 2 |
Completed |
NCT05211030 |
| Closed-Loop BCI Therapy |
Adaptive BCI |
Phase 1 |
Recruiting |
NCT06006179 |
| Trial Name |
Device/Intervention |
Phase |
Status |
NCT Number |
| Responsive Neurostimulation |
RNS System |
Post-Market |
Active |
NCT00570198 |
| ECoG-Based Seizure Prediction |
ECoG BCI |
Phase 2 |
Recruiting |
NCT05467878 |
- Primary Goal: Safety and tolerability
- Participants: Small group (10-50)
- Duration: Several months
- Focus: Identify adverse effects, determine safe dosage range
- Primary Goal: Efficacy and side effects
- Participants: Larger group (100-300)
- Duration: Several months to years
- Focus: Compare treated vs. control groups
- Primary Goal: Confirm efficacy
- Participants: Large group (1,000-3,000)
- Duration: 1-4 years
- Focus: Monitor adverse reactions, compare to standard treatments
- Primary Goal: Long-term safety
- Participants: Large populations
- Duration: Ongoing
- Focus: Long-term effects, cost-effectiveness
- Age: 18-75 years (varies by trial)
- Diagnosis: Confirmed neurodegenerative condition
- Disease Severity: Moderate to severe impairment
- Cognitive Function: Able to provide informed consent
- No Contraindications: No MRI incompatibilities, no active infections
- Psychiatric Disorders: Active severe depression or psychosis
- Cognitive Impairment: MMSE score below threshold
- Seizure History: Active epilepsy (for some trials)
- Metal Implants: MRI-incompatible devices
- Pregnancy: Current pregnancy or planning pregnancy
- Communication Speed: Words per minute (for communication BCIs)
- Motor Function: Fugl-Meyer Assessment, Motor Assessment Scale
- Quality of Life: EQ-5D, SF-36, disease-specific scales
- Adverse Events: Frequency and severity of complications
- Neural Signal Quality: Signal-to-noise ratio, classification accuracy
- Device Reliability: Uptime, maintenance requirements
- User Satisfaction: System Usability Scale, device preference
- Long-term Outcomes: 1-5 year follow-up measures
| Company |
Device |
Year |
Indication |
| Neuralink |
N1 |
2020 |
Paralysis |
| Synchron |
Stentrode |
2020 |
Paralysis |
| Paradromics |
Connexus |
2023 |
Communication |
| Precision Neuroscience |
Layer 7 |
2023 |
Epilepsy |
- Synchron Stentrode: CE Marked (2022)
- g.tec recovery: CE Marked (2021)
- MindMaze: CE Marked (2020)
- Stanford University: BrainGate consortium
- University of Pittsburgh: Neural engineering lab
- UCLA: Neural computation lab
- Massachusetts General Hospital: Clinical trials
- University of Tübingen: BCI research (Germany)
- Charité Berlin: Neurotechnology (Germany)
- University of Oxford: Neural interface research (UK)
- Tokyo University: RIKEN BCI program (Japan)
- Tsinghua University: Neural engineering (China)
- Memory Prosthetic BCI: Trials for Alzheimer's-related memory impairment
- Bidirectional Neural Interfaces: Reading and writing to neural tissue
- Fully Implantable Systems: No external hardware requirements
- Personalized Decoding: AI-based individual optimization
- Huntington's Disease: Motor and cognitive symptom management
- Multiple Sclerosis: Fatigue management and motor recovery
- Traumatic Brain Injury: Cognitive rehabilitation
- Chronic Pain: Neuromodulation for pain management